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This article demarcated the end of the experimental phase of 
clinical liver transplantation from the beginning of the 
procedure's widespread therapeutic use. 
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The "evolution" article of 1982 heralded the acceptance of a 
procedure first attempted in 1963 (1) but not with extended 
patient survival until 1967 (2). Liver replacement remained an 
orphan operation from 1967-79, sustained by our Colorado program 
at the University of Colorado (Denver), which was joined in 1967 
by Roy Calne's team at Cambridge University (England). In 
Denver, only 56 recipients survived for 1 year of 170 treated 
between 1963 and 1979; 22 are still living after 14-24 years. 
The English results were no better, but all the while technical 
and management advances were being made. Cocktail 
immunosuppression which had been developed in kidney recipients 
(3) was with azathioprine combined with the highly dose 
maneuverable adrenal cortical steroids to which adjuvant ALG was 
added in 1966 (4). In 1979, CaIne, the team leader 2 decades 
before in the preclinical development of azathioprine, reported 
the first cyclosporine trials in 34 patients including 2 liver 
recipients (5). By substituting cyclosporine for azathioprine in 
our 2 or 3-drug cocktails in 1979-80, the full potential of the 
new drug was realized in Colorado, first in kidney and then liver 
recipients of whom 11 of the first 12 survived for more than one 
year (6). More liver cases by the same team (now in Pittsburgh) 
in 1981-82 were confirmatory. 
In December, 1981, I personally reported to C. Everett Koop, 
the Surgeon General, that the impending revolution in 
transplantation would include the liver, and Koop initiated a 
Consensus Development Conference for liver transplantation. 
Although this was not held until June 20-23, 1983, its planning 
in Washington took place in June 1982, where Roy CaIne was 
invited as a consultant with a side visit to Pittsburgh. I was 
putting the finishing touches on the evolution manuscript which 
was scheduled for oral presentation at the American Association 
for the Study of Liver Diseases (AASLD) on November 1 with 
simultaneous pUblication in Hepatology. CaIne reviewed the 
article and was given the data for his impending liver transplant 
overview to the Transplantation Society in August. The 
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manuscript summarized the entire Colorado-Pittsburgh experience 
and that elsewhere from 1963 through early 1982, and stratified 
this into the dramatically different pre- and post-cyclosporine 
eras. At the Consensus Development Conference 8 months later, 
liver transplantation was declared a service as opposed to an 
experimental procedure, beginning a stampede to start new liver 
transplant centers. 
The events up to the evolution paper were before the 
commercialism of liver transplantation, when the purity and 
purpose (if not the seeming wisdom) of the crusade were palpable. 
By 1989, essentially all of the positions taken in the 1982 
article, including the indications for liver transplantation, had 
been verified (7). Honors and awards resulted, but these meant 
little compared to the satisfaction of seeing a population grow 
of well patients who only one generation previously were 
consigned to early death, and of watching the burgeoning careers 
of physicians and surgeons who had trained in our programs. The 
achievements were theirs, and when I stopped clinical work, I 
wrote their story in a book called "The Puzzle People" (8). The 
book also described a mutually supportive professional 
relationship with CaIne and his British team which might be 
emulated by those who become so competitive that they erode the 
respect and affection that should come naturally between 
companions in a common cause. 
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